Results 231 to 240 of about 10,292,063 (293)

Effectiveness and safety of interleukin 6 receptor inhibitors versus conventional immunomodulatory therapy in steroid-refractory polymyalgia rheumatica. [PDF]

RMD Open
Dua AB, Spiera RF, Dikranian A, Calabrese C, Bingham CO, Ford K, Fiore S, Araujo L, Petruski-Ivleva N, Isaman DL, Xie F, Curtis JR.   +11 more
europepmc   +1 more source

Redirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy

Advanced Science, EarlyView.
A dual‐targeting engineered extracellular vesicles (M1‐CS‐EVs) platform is developed to redirect monocytes differentiation into anti‐tumor macrophages for glioma immunotherapy. This nanoplatform combines CAR‐mediated tumor recognition with localized CD47 blockade, leading to synergistic immune activation and potent suppression of tumor progression in ...
Yuanwei Pan, Xuan Liu, Qian‐Fang Meng, Lei Cao, Rongrong Li, Yangtao Xu, Jing Zhang, Chenchen Zhao, Lang Rao, Chen Yu   +9 more
wiley   +1 more source

Discriminative Role of Interleukin-6, Neuropilin-1, and Amphiregulin for Cirrhosis in Patients with Chronic Hepatitis B Infection. [PDF]

Turk J Gastroenterol
Karakoc Ozudogru F, Karaca B, Turker N, Ormen B, Vatansever S, Erbak Yılmaz H, Karalar FO, Gunsar F, Sener A.   +8 more
europepmc   +1 more source

USP5 Stabilizes TGFBR1 to Drive Vascular Smooth Muscle Cell Senescence and Atherosclerosis

Advanced Science, EarlyView.
This study reveals that USP5 drives vascular smooth muscle cell senescence and atherosclerosis by stabilizing TGFBR1, suppressing IDH2, and promoting glycolytic reprogramming, identifying the USP5‐TGFBR1‐IDH2 axis as a potential therapeutic target. ABSTRACT Vascular smooth muscle cell (VSMC) senescence contributes importantly to atherosclerotic plaque ...
Xinhai Cui, Yuanlong Hu, Lin Lin, Lei Zhang, Chao Li, Yunlun Li   +5 more
wiley   +1 more source

Interleukin-6 as an Oral-Vascular Inflammatory Bridge: Integrating CXCL10 and Haptoglobin 2-2 into a Potential Model of Periodontitis-Associated Cardiovascular Risk. [PDF]

Int J Mol Sci
Vigerust DJ, Bale BF.
europepmc   +1 more source

Effect of Interleukin-6 Inhibitors on Rheumatoid Arthritis Pain: Overview of Evidence and Mechanistic Pathways. [PDF]

Pharmacol Res Perspect
Belančić A, Sener S, Fajkić A, Potočnjak I, Benić MS, Vučković M, Sener YZ, Pavlović MR, Markotić A, Radić J, Radić M.   +10 more
europepmc   +1 more source

Interleukin-6 Inhibition for Patients with Acute Myocardial Infarction: <i>A Systematic Review and Meta-Analysis</i>. [PDF]

Saudi Med J
Alasmary MY, Almalki MJ, Almalki FH, Khubzan WD, Rajab MH, Almalki MS, Almalki HA, Alsuwat OM, Alghannami HM.   +8 more
europepmc   +1 more source

Exosomal 3'tiRNA-PheGAA and interleukin-6 as novel biomarkers for non-invasive detection of NSCLC. [PDF]

Discov Oncol
Yuan N, Zhang Q, Shi J, Cheng W, Zhao B, Zhang Z.   +5 more
europepmc   +1 more source

Interleukin-6 is associated with white matter hyperintensities and cognition independent of Alzheimer's disease plasma biomarkers-HABS-HD. [PDF]

J Alzheimers Dis
Dharmapuri A, Chaudhuri S, Contreras JA, Hayes CA, Health and Aging Brain Study (HABS-HD) Study Team *.   +4 more
europepmc   +1 more source

Elevated interleukin-6 levels predict short-term flare in systemic lupus erythematosus. [PDF]

Front Immunol
Gracia Tello BDC, García-Bruñén JM, Corredor L, Allue Fantova N, Calvo Beguería EM, García-Muñío R, Pérez Abad L, Aramburu Llorente J, Martinez Muriel B, Vidales Miguélez P, Morante Mendoza RA, Martínez Artigot J, Chicano Nieto N, Álvarez Troncoso J, Martinez-Lostao L, Marín Ballvé A.   +15 more
europepmc   +1 more source